Zynerba Pharmaceuticals, Inc. (ZYNE)
Zynerba Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Devon, PA, US. The stock last traded at $1.30, up 2.36% on the session, giving a market capitalisation of $70.1M. On trailing twelve-month figures it carries a trailing P/E of -1.59, a net margin of 0.0%. Its beta of 1.19 implies it has historically moved more than the broad market.
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Zynerba Pharmaceuticals, Inc. is most often compared with the following Healthcare names: